Daniel G. Chain, PhD
Dr. Chain is a seasoned biotechnology executive and scientist entrepreneur dedicated to the development of therapeutics for the treatment of Alzheimer’s and other neurodegenerative diseases. For 18 years, he has established and managed companies in the neurodegeneration field, and his patented innovations helped enable the development of several monoclonal antibodies being studied for Alzheimer’s disease targeting beta amyloid and tau. In addition, Dr. Chain spearheaded the development of a metal binding antioxidant compound currently under development for Friedreich’s Ataxia by Shire Pharmaceuticals. Dr. Chain was approached on behalf of Chiesi Farmaceutici S.p.A. to assume responsibility for the development and commercialization of CSP-1103 (formerly CHF 5074), which led to his decision to found CereSpir in the summer of 2013 and license the technology from Chiesi obtaining worldwide rights. Dr. Chain trained as a biochemist and molecular neurobiologist having obtained his PhD from the Weizmann Institute of Sciences in Israel and subsequently trained as a researcher at Columbia College of Physicians and Surgeons in New York.
Adrian N. Hobden, PhD
President and Chief Executive Officer
Dr. Hobden has a long and distinguished career in the global pharmaceutical industry. He joined Glaxo in the United Kingdom as a research scientist in 1981 and went on to run their Genetics Department and several others, including CNS Pharmacology. He moved to the United States in 1996 and was responsible for Glaxo’s collaborations with biotechnology companies. In 1998, Dr. Hobden joined Myriad Genetics in Salt Lake City as President of Myriad Pharmaceuticals which he founded and grew into an integrated R&D organization of 220 employees with responsibility to manage the largest placebo controlled trial of an experimental Alzheimer medicine that had ever been run. Myriad Pharmaceuticals was later spun out as a public company called Myrexis with Dr. Hobden as CEO. He retired from Myrexis in 2011. Currently, Dr. Hobden is also a board member at Zocere Inc, a startup biotechnology company focused on the development of novel compounds for the treatment of stroke and brain trauma and a trustee of The Hope Funds for Cancer Research. Dr Hobden has a BA and MA in Natural Sciences from the University of Cambridge and a Ph.D. in Molecular Biology from the University of Leicester.